Northeast Financial Consultants Inc Immuno Gen, Inc. Transaction History

Northeast Financial Consultants Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 12, 2019	BUY	$3.94 - $9.7 $135,201 - $332,855	34,315 New	34,315 $165,000
Q3 2018 Nov 08, 2018	SELL	$8.6 - $11.26 $295,109 - $386,386	-34,315 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$5.4 - $8.47 $185,301 - $290,648	34,315	34,315 $263,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Northeast Financial Consultants Inc, based on Form 13F filings with the SEC.

Stay updated on Northeast Financial Consultants Inc with notifications on news.